{
  "id": 20371309,
  "title": "Belite Bio CMO Scholl sells $331,976 in shares",
  "url": "https://urgent.news/2026/11/17/belite-bio-cmo-scholl-sells-331-976-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-17T02:46:05.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/belite-bio-cmo-scholl-sells-331976-in-shares-93CH-5031512"
  },
  "original_language": "en",
  "account": "Hendrik Peter Scholl, the Chief Medical Officer of BELITE BIO, INC (NASDAQ:BLTE), recently sold $331,976 worth of American depositary shares on November 12, 2026. The shares were sold in increments of 2,000, with prices fluctuating between $162.0394 and $170.4094. Currently, the stock is priced at $162.56, reflecting a 39% increase over the past year. InvestingPro analysis indicates that the shares might be undervalued in comparison to their Fair Value estimate. The sales were facilitated indirectly through Bioptima Ltd., and the transactions were conducted following a Rule 10b5-1 trading plan that Scholl established on June 25, 2026.\n\nTwo analysts have recently revised their earnings estimates upward for the upcoming period, according to InvestingPro, which tracks 10 additional ProTips for BLTE. After completing these transactions, Scholl, through Bioptima Ltd., retains ownership of 12,500 American depositary shares. Notably, BELITE BIO, INC recently released its third-quarter 2026 results, revealing an adjusted loss of minus $0.60 per share, which outperformed analysts’ predictions of minus $0.79. This marked a 24.05% surprise, while total revenue stood at $0, as expected. The most significant development in BELITE BIO, INC's recent news is the FDA's decision not to mandate an advisory committee meeting for the new drug application of tinlarebant under Priority Review. The FDA set a target decision date for the application on February 12, 2027.\n\nFollowing this update, Mizuho increased its price target for BELITE BIO, INC to $230 from $221, and the firm maintained an Outperform rating. StoneX also reiterated its Buy rating with a $217 price target, considering the FDA's decision as a positive sign. These developments underscore heightened confidence in BELITE BIO, INC's prospects for regulatory success. The article was produced with the assistance of AI and reviewed by an editor. For further information, see the Terms and Conditions.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}